Altium Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Altium Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75,000	Closed	-$6.26M	–	72
2024 Q4	$6.26M	Sell	75,000 -79,000	-51%	-$6.49M	1.78%	18
2024 Q3	$11.3M	Sell	154,000 -39,000	-20%	-$2.93M	3.32%	7
2024 Q2	$13.2M	Buy	193,000 +80,000	+71%	+$5.55M	5.39%	4
2024 Q1	$7.82M	Buy	113,000 +42,000	+59%	+$2.89M	3.09%	11
2023 Q4	$5.09M	Buy	71,000 +43,000	+154%	+$2.47M	3.45%	12
2023 Q3	$1.46M	Buy	+28,000	New	+$1.63M	0.76%	30
2023 Q1	–	Sell	-100,000	Closed	-$5.29M	–	115
2022 Q4	$5.29M	Hold	100,000	–	–	2.69%	9
2022 Q3	$4.65M	Buy	100,000 +25,000	+33%	+$1.31M	1.71%	12
2022 Q2	$4.28M	Buy	75,000 +52,500	+233%	+$2.98M	1.71%	14
2022 Q1	$1.38M	Buy	+22,500	New	+$1.17M	0.46%	69
2021 Q2	–	Sell	-88,326	Closed	-$3M	–	160
2021 Q1	$3M	Sell	88,326 -65,022	-42%	-$2.26M	0.83%	50
2020 Q4	$4.88M	Buy	+153,348	New	+$4.03M	1.82%	13

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Altium Capital Management's ITCI Position: Q1 2025 in Review

Altium Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 75,000 shares — an estimated $6.26M sold.

Altium Capital Management first reported a position in ITCI in Q4 2020 and held it in 12 quarters. The position peaked at $13.2M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Altium Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Altium Capital Management sold 75,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $6.26M.
Altium Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 12 quarters.
Altium Capital Management's Intra-Cellular Therapies Inc. position peaked at $13.2M in Q2 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.